Back to Oral Cavity Squamous Cell Carcinoma

Oral Cavity Squamous Cell Carcinoma — Clinical Trials

MONDO:000495888 active·50 recruitingLast updated: Mar 16, 2026, 6:12 AM

Trial Landscape

Oral Cavity Squamous Cell Carcinoma has an active clinical trial landscape, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment52

Procedure43

Biological Therapy17

Medical Device7

28 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

30 trials are observational or have no phase designation.

Sponsor Types

Academic/Other68NIH14Industry4Collaborative Network2

Top Sponsors

Alpha Tau Medical LTD.

Privo Technologies

Viome

Trial Locations

United States42 trials

China19 trials

Canada6 trials

France5 trials

Italy4 trials

Germany3 trials

India2 trials

South Africa2 trials

Netherlands2 trials

Hong Kong1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

88 Trials

Phase 3Recruiting

NCT06589804

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2025Est. completion: Nov 2029Updated: Mar 2026

Phase 3Recruiting

NCT07371611

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Sponsor:Qunxing Li,MD

ChinaStarted: Jan 2026Est. completion: Dec 2033Updated: Jan 2026

Phase 3Recruiting

NCT06258811

Neoadjuvant Immunochemotherapy for LAOSCC

Sponsor:Lai-ping Zhong

ChinaStarted: Feb 2024Est. completion: Dec 2028Updated: Mar 2025

Phase 3Recruiting

NCT05798793

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Sponsor:Hospital of Stomatology, Wuhan University

ChinaStarted: Nov 2023Est. completion: Oct 2026Updated: Apr 2024

Last updated over 18 months ago

Phase 2Recruiting

NCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Apr 2021Est. completion: Jun 2029Updated: Mar 2026

Phase 2Recruiting

NCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2013Est. completion: Jan 2027Updated: Mar 2026

Phase 2Recruiting

NCT07195734

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2026Est. completion: Feb 2033Updated: Mar 2026

Phase 2Recruiting

NCT06980038

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2026Est. completion: Nov 2027Updated: Mar 2026

Phase 2Recruiting

NCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2022Est. completion: Jan 2027Updated: Mar 2026

Phase 2Recruiting

NCT06030440

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Sponsor:University of Erlangen-Nürnberg Medical School

GermanyStarted: Jan 2024Est. completion: Sep 2033Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT05721755

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:ECOG-ACRIN Cancer Research Group

United StatesStarted: Jun 2023Est. completion: Mar 2030Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT00588770

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2008Est. completion: Feb 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05063552

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2023Est. completion: Dec 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05172258

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Jun 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04862650

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:Marcelo Bonomi

United StatesStarted: Nov 2021Est. completion: Dec 2026Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT03468218

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Sponsor:Emory University

United StatesStarted: Sep 2018Est. completion: Oct 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT00494182

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Apr 2007Est. completion: Dec 2026Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT03854032

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Sponsor:Thomas Jefferson University

United StatesStarted: Apr 2019Est. completion: Dec 2025Updated: Jun 2025

Phase 2Active, Not Recruiting

NCT06009861

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Sponsor:Peking University Hospital of Stomatology

ChinaStarted: Jun 2023Est. completion: Jun 2027Updated: Jun 2025

Phase 2Active, Not Recruiting

NCT04718415

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

Sponsor:Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

ChinaStarted: Jan 2021Est. completion: Jan 2027Updated: Sep 2024

Last updated over 18 months ago

Stay informed about clinical trials for Oral Cavity Squamous Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 6:12 AM

Oral Cavity Squamous Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

88 Trials

Open Trials71

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Neoadjuvant Immunochemotherapy for LAOSCC

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Active Trials17

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma